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Background and aims: Familial hypercholesterolaemia (FH) is a major cause of premature heart disease
but remains unrecognised in most patients. This study investigated if a systematic primary care-based
approach to identify and manage possible FH improves recommended best clinical practice.
Methods: Pre- and post-intervention study in six UK general practices (population 45,033), which invited
patients with total cholesterol >7.5mmol/L to be assessed for possible FH. Compliance with national
guideline recommendations to identify and manage possible FH (repeat cholesterol; assess family history
of heart disease; identify secondary causes and clinical features; reduce total & LDL-cholesterol; statin
prescribing; lifestyle advice) was assessed by calculating the absolute difference in measures of care pre-
and six months post-intervention.
Results: The intervention improved best clinical practice in 118 patients consenting to assessment (of 831
eligible patients): repeat cholesterol test (þ75.4%, 95% CI 66.9e82.3); family history of heart disease
assessed (þ35.6%, 95% CI 27.0e44.2); diagnosis of secondary causes (þ7.7%, 95% CI 4.1e13.9), examining
clinical features (þ6.0%, 95% CI 2.9e11.7). For 32 patients diagnosed with possible FH using Simon-
Broome criteria, statin prescription signiﬁcantly improved (18.8%, 95% CI 8.9e35.3), with non-
signiﬁcant mean reductions in cholesterol post-intervention (total: 0.16mmol/L, 95% CI -0.78-0.46;
LDL: 0.12mmol/L, 95% CI -0.81-0.57).
Conclusions: Within six months, this simple primary care intervention improved both identiﬁcation and
management of patients with possible FH, in line with national evidence-based guidelines. Replicating
and sustaining this approach across the country could lead to substantial improvement in health out-
comes for these individuals with very high cardiovascular risk.
© 2018 The Authors. Published by Elsevier B.V. This is an open access article under the CC BY-NC-ND
license (http://creativecommons.org/licenses/by-nc-nd/4.0/).1. Introduction
Familial hypercholesterolaemia (FH) is the most common
autosomal dominant disorder with at least 1 in 500 individuals
affected in the general population [1]. Over 80% of an estimated
120,000 individuals in the United Kingdom remain undiagnosed,
with similar rates of under-diagnosis across Europe, which results
in major lost opportunities to prevent premature heart disease and
death [2]. Left untreated, coronary heart disease (CHD) will develop
in approximately 50% of men with FH by the age of 50 and 30% of1403 The Tower, University
(S. Weng).
B.V. This is an open access article uwomen with FH by the age of 60 [3]. This results in a 100-fold in-
crease in mortality risk compared to the general population [4,5].
This can be very effectively reduced by high intensity lipid lowering
treatment, resulting in a 48% reduction in CHD mortality [6].
Despite established national clinical guidelines in several
countries [7e9], people with raised cholesterols are not recognised
as having FH. In the UK, cholesterol levels are well captured in
primary care electronic health records, offering the opportunity to
improve recognition and quality of care of this condition. The En-
glish National Institute for Health and Care Excellence (NICE)
guidelines introduced in 2008 [8], recommend general practi-
tioners (GPs) use Simon-Broome diagnostic criteria to identify FH
[10]. These state individuals with cholesterol levels over 7.5mmol/L
and a relevant family history of premature CHD be diagnosed asnder the CC BY-NC-ND license (http://creativecommons.org/licenses/by-nc-nd/4.0/).
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conﬁrmation of diagnosis.
Combining a search of general practice electronic medical re-
cords for patients with elevated cholesterol and systematic
collection of family history may improve identiﬁcation of possible
FH [11e13]. This should be accompanied by better recording of
clinical features of FH and excluding secondary causes of raised
cholesterol [8]. Further, proactive case ascertainment should also
improve lipid management. This study aimed to assess whether
such a proactive approach to identify possible familial hyper-
cholesterolaemia (FH) in primary care improves best practice in
accord with national guideline recommendations on identifying
and managing FH [8].
2. Materials and methods
2.1. Study design
This was a pre- and post-intervention study over 17 months,
which ended in Aug 2015. Ethical approval granted by the NRES
Committee West Midlands e Solihull (Reference 12/WM/0322).
The baseline (pre-intervention period) was deﬁned as the 6-
month period fromwhen a participants' total cholesterol was found
to be 7.5mmol/L after the release of the NICE FH guidelines in
November 2008. The intervention was ﬁrst introduced at various
time points from March 2013 (ﬁrst practice recruited) to January
2014 (last practice recruited). During this period, participants with
total cholesterol levels 7.5mmol/L were invited to complete a
family history questionnaire. If the family history was positive, the
patients was then offered further clinical assessment over a six
month period (post-intervention period). This process is shown in
Fig. 1.
2.2. Participants
All general practices in Nottingham (East Midlands, UK) were
invited to participate in this study. We received initial expressions
of interest from 18 general practices. Six of these practices
responded (33.3%) following provision of further study informa-
tion, and all these were recruited (four inner city, one suburban,
one rural).
Patients from each of the six practices were eligible if they were
aged 18 years or over, with a total cholesterol level greater than
7.5mmol/L documented in their primary care electronic health
records (EHRs). Participants with a conﬁrmed diagnosis of familialFig. 1. Study process: pre- and dhypercholesterolaemia were excluded. Full details of participant
recruitment are reported elsewhere [14]. Written informed consent
was obtained from each patient included in the study as outlined in
the study protocol which conforms to the ethical guidelines of the
1975 Declaration of Helsinki and has been prior approved by the
Institution's ethics committee on research on humans.
2.3. Intervention and procedure
The intervention consisted of an educational session with gen-
eral practitioners and practice nurses which lasted an hour on case-
identiﬁcation and assessment of FH using Simon-Broome diag-
nostic criteria recommended in the current NICE guidelines [8]. The
computer-based reminder message that appears when they
accessed eligible participants' records in patient consultations was
also demonstrated.
A baseline data extraction from electronic health records (EHR)
was then completed to identify eligible participants and their
electronic health records were tagged with a reminder message
whenever the record was accessed in a consultation. In line with
NICE FH guidelines [8], this prompted their GP to opportunistically
assess for secondary causes of raised cholesterol, ask participants to
complete Family History and Symptom Questionnaires (FHSQ) and
repeat lipid proﬁle, Four months into the intervention, eligible
participants not yet invited opportunistically by practitioners were
contacted through postal invitation by their practice.
Postal invitations included requests to conduct a follow-up
fasting lipid test and complete the FHSQ. After return of the
FHSQ, a research assistant collated fasting lipid results, current
family history information, statin therapy, and notiﬁed GPs and
participants if there was any possibility of a FH diagnosis based on
NICE Simon-Broome criteria [8]. Post-intervention, we then
assessed GP compliance to national (NICE) guideline recommen-
dations on best clinical practice for FH identiﬁcation and
management.
2.4. Outcome measures
Outcome measures for compliance to NICE guideline recom-
mendations were assessed for all recruited participants at the end
of the pre-intervention period (Fig. 1, Time 2) and at the end of the
intervention period (post-intervention) (Fig. 1, Time 4), including:
(i) Assessment for FH in patients with elevated cholesterol (ii)
Management of patients who have been diagnosed with possible
FH. (see Table 1; further detail is available in Supplementary Data).uring intervention periods.
S. Weng et al. / Atherosclerosis 274 (2018) 54e6056These outcomemeasures were also extracted from general practice
EHRs at the end of each six month period. Extraction from EHRs
was performed using automated data extraction via medical codes
and manual clinical record review for free-text entries and hospital
correspondence.
For the assessment of FH in patients with elevated cholesterols,
the primary outcome measure was deﬁned as the difference in the
proportion of patients with any family history of coronary heart
disease (CHD) documented in their EHRs between pre- and post-
intervention periods. Other outcome measures related to diag-
nostic assessment include the difference; between pre- and post-
intervention periods in proportions of: patients with repeated
cholesterol tests, diagnoses of secondary causes, biomarkers for
secondary causes measured (TSH, HbA1c, serum creatinine, liver
function tests), diagnoses of arcus senilis or xanthalasma. GPs in the
study were advised to speciﬁcally assess for arcus cornealis and
tendon xanthoma but code in the electronic health records as arcus
senilis and generic xanthalasma due to limited availability of rele-
vant NHS read codes.
For the management of those diagnosed with possible FH, the
outcomes were change in total cholesterol, LDL cholesterol, as well
as, difference in proportions of patients taking statin treatment
(any and high potency), given advice for managing diet and weight,
and given advice to stop smoking.2.5. Sample size calculation
For the primary outcome measure, a sample size of 118 patients
from the six practices would allow an absolute increase of 10% in
the proportion of patients with family history of CHD recorded in
EHRs to be determinedwith 95% conﬁdence intervals towithin ±7%
(i.e. 95% CI 3%e17%), assuming a baseline of 3.7% from a previous
study [15].2.6. Statistical analysis
A descriptive analysis was conducted presenting numbers and
percentages for all categorical outcome variables, with continuous
variables of total cholesterol and LDL-cholesterol presented as
mean and standard deviation, stratiﬁed by gender. To evaluate ef-
fects of the intervention on compliance to NICE guideline recom-
mendations, we calculated the change in absolute difference for
proportions with 95% conﬁdence intervals (Wald's method based
on normal approximation) [16] for categorical outcomes and mean
difference with 95% conﬁdence intervals [17] for continuousTable 1
Outcome measures for compliance to NICE Familial Hypercholesterolaemia Guideline (C
Assessment for diagnosing familial hypercholesterolaemia (NICE CG71 Section 1.1
Proportion of patients with any family history of coronary heart disease assessed
Proportion of patients with complete family history (age, condition, degree of relation
Proportion of patients with repeat cholesterol test
Proportion of patients diagnosed with secondary cause (diabetes, hypothyroidism, chr
Proportion of patients with TSH assessment (proxy for hypothyroidism investigations
Proportion of patients with HbA1c assessment (proxy for diabetes investigation)
Proportion of patients with serum creatinine assessment (proxy for chronic kidney dis
Proportion of patients with bilirubin, ALP, or gamma GT assessment (proxy for liver d
Proportion of patients with arcus senilis or xanthalasma diagnosed
Management of diagnosed possible familial hypercholesterolaemia (NICE CG71 Se
Total cholesterol levels (mmol/L)
LDL cholesterol levels (mmol/L)
Proportion of patients prescribed any statin treatment
Proportion of patients prescribed high potency statin treatment (Simvastatin 80mg/
Proportion of patients given dietary or weight management advice
Proportion of patients given smoking cessation advicecholesterol outcomes, between pre- and post-intervention periods.
Continuous cholesterol variables were investigated for normality
and if needed, were log-transformed for better ﬁt. All analyses were
conducted in STATA 14 MP4.
2.7. Ethical approval
Approved by NRES Committee West Midlands e Solihull
(Reference 12/WM/0322).
3. Results
3.1. Study participants
In the six participating practices, there were 45,033 total pa-
tients registered on the baseline date. Baseline searches identiﬁed a
total of 831 eligible patients who were at least 18 years of age who
had total cholesterol greater than 7.5mmol/L, and without a pre-
vious diagnosis of FH (1.84% of practice population). Six patient
were excluded at baseline as they had a previous diagnosis of FH.
During the 6 month intervention period, 127 of the 831 eligible
patients (15.3%) consented to participate, two were excluded (one
declined lipid test, one had a previous diagnosis of FH). Of the 125
eligible patients, 118 patients' medical records could be accessed (7
left the practice during study period). Thirty-two (27.1%) of the
remaining 118 eligible patients met NICE Simon-Broome diagnostic
criteria for possible FH, with two patients conﬁrmed with deﬁnite
FH. Further study details on participants with possible FH are
provided elsewhere [14].
3.2. Characteristics of study participants in the pre-intervention
period
Comparing males and females (Table 2), in the 118 patients with
baseline data, there were more females than males (61% vs. 39%),
and the males were slightly older. The mean total cholesterol was
also slightly higher in females, as was mean LDL-cholesterol and
proportion with elevated cholesterol (total or LDL).
Considering potential opportunities for diagnosis of FH, after the
release of NICE FH guidelines (CG71) in November 2008, median
datewhen a total cholesterol 7.5mmol/L was documentedwas 10
May 2009 for men and 8 February 2010 for women. During the pre-
intervention period, cholesterol testing was repeated in only 1 man
(2%) and 11 women (15%), whilst the proportionwith family history
documented (both complete and any family history of CHD wasG71) recommendations.
)
) of coronary heart disease assessed
onic kidney disease, liver disease)
)
ease investigations)
isease)
ction 1.3)
day; Atorvastatin 20mg/day; Rosuvastatin 10mg/day)
Table 2
Descriptive characteristics of recruited patients in pre-intervention period, extracted from electronic health records (EHRs) andmanual review. Variables are
means and standard deviations unless otherwise speciﬁed.
Patient characteristics Male (n¼ 46) Female (n¼ 72)
Age (years) 58 (9.0) 56 (7.5)
Family history of coronary heart disease assessed (%) 3 (6.5) 4 (5.6)
Complete family historya of coronary heart disease assessed (%) 1 (2.2) 2 (2.7)
Repeat cholesterol test (%) 1 (2.2) 11 (15)
Diagnosed with secondary causeb (%) 3 (6.5) 2 (2.7)
TSH assessedc (%) 28 (61) 37 (51)
HbA1c assessedd (%) 16 (35) 23 (32)
Serum creatinine assessede (%) 38 (83) 65 (90)
Bilirubin, ALP, or gamma GT assessedf (%) 37 (80) 62 (86)
Arcus senilis or xanthalasma diagnosed (%) 0 (0.0) 1 (2.2)
Mean total cholesterol (mmol/L) 6.1 (1.6) 6.6 (1.5)
Mean LDL cholesterol (mmol/L) 3.8 (1.7) 4.0 (1.5)
Prescribed statins (%) 8 (17) 10 (14)
Prescribed high potency statinsg (%) 2 (4.3) 4 (5.6)
Given dietary or weight management advice (%) 22 (48) 34 (47)
Given smoking cessation advice (%) 4 (8.7) 8 (11)
a Complete family history is deﬁned when age, condition, and degree of relation to patient is documented.
b Diabetes, hypothyroidism, chronic kidney disease, liver disease.
c Proxy for secondary investigations for hypothyroidism.
d Proxy for secondary investigations for diabetes.
e Proxy for secondary investigations for chronic kidney disease.
f Proxy for secondary investigations for liver disease.
g Simvastatin 80mg/day, atorvastatin 20mg/day, rosuvastatin 10mg/day.
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and women (any family history assessed: 6.5% of men compared to
5.6% of women; complete family history assessed: 2.2% of men
compared to 2.7% of women). Considering workup of patients,
during six months pre-intervention period, clinical features of FH
(arcus or xanthelasma) and diagnosis of secondary cause were
uncommon, whilst investigation of secondary causes was better
recorded. Further, during this pre-intervention period, statins were
only prescribed for 8 men (17%) and 10 women (14%); of which 2
men (4%) and 4 women (6%) were prescribed high potency statins.
Considering lifestyle advice, dietary or weight management advice
was given to around 47% of both genders, with smoking cessation
advice offered to around 10% of patients.
3.3. Guideline compliance in assessing individuals for familial
hypercholesterolaemia
Compliance to guideline recommendations for assessing FH at
the end of the pre-intervention and intervention periods (post-
intervention) are shown in Table 3. First, considering identiﬁcation
of FH, over a third of the 118 patients (35.6%, 95% CI 27.0 to 44.2)
had a family history of coronary heart disease documented. There
was also a smaller but signiﬁcant increase (6.8%, 95% CI 3.5 to 12.8)
in documenting a complete family history (age, coronary heart
disease, and degree of relation). There was a much greater increase
in the proportion of patients receiving repeat cholesterol tests
(75.4%, 95% CI 66.9 to 82.3), whilst there was a small but signiﬁcant
increase in examination for clinical features: with 7 more patients
(6.0%, 95% CI 2.9 to 11.7) having arcus senilus or xanthalasma
documented in records. There were similar levels of increasing
diagnosis of secondary causes (7.7%, 95% CI 4.1 to 13.9) and inves-
tigating causes of raised cholesterol (from 6.8% for liver function
tests to 12.7% for serum creatinine).
3.4. Guideline compliance in managing possible familial
hypercholesterolaemia
Compliance to guideline recommendations for managing pa-
tients diagnosed with possible FH at the end of the pre-
intervention and intervention periods (post-intervention) areshown in Table 4.
Considering the possible impact of intervention on cholesterol
management, compared to pre-intervention period, total choles-
terol and LDL cholesterol at the end of the intervention period was
not signiﬁcantly reduced in these 32 patients with possible FH
(total cholesterol: mean difference: 0.16mmol/L, 95% CI -0.78 to
0.46; LDL cholesterol: mean difference: 0.12mmol/L, 95% CI -0.81
to 0.57). However, there was a large and signiﬁcant increase in
statin prescribing for these 32 patients (18.8%, 95% CI 8.9 to 35.3).
This difference was smaller but remained signiﬁcant for prescribing
a high potency statin (9.4%, 95% CI 3.2 to 24.2). Lifestyle risk
reducing advice for coronary heart disease, as indicated by diet or
weight management and smoking cessation, showed little recor-
ded improvement pre- and post-intervention.
4. Discussion
This study suggests that a simple intervention in primary care
can improve assessment and identiﬁcation of possible familial
hypercholesterolaemia among patients with high cholesterol.
These patients accounted for almost 2% of the whole general
practice population, highlighting the scale and need for assess-
ment. Despite short follow-up period, the study demonstrated
some improvement in management of patients with possible FH.
Sustaining this effort over a longer period of time could potentially
yield even greater gains.
Considering compliance with national recommendations on
assessing patients for FH, repeat cholesterol testing and family
history recording improved considerably, with more modest im-
provements in recommended completeness of family history
recording and assessment of clinical signs. The intervention had
more limited impact on investigation and diagnosis of secondary
causes of FH.
Considering management of possible FH, statin prescribing
improved greatly, with more modest improvement in high potency
statin prescribing. Together with the short (six month) follow-up
period, this may explain the smaller than expected improvements
in cholesterol levels. There was also room for improvement in
lifestyle risk-reducing advice. However, the baseline lifestyle advice
given was quite high.
Table 3
Change in compliance (absolute difference) to outcomes for assessing familial hypercholesterolaemia in 118 patients with elevated cholesterol.
NICE compliance outcomes for diagnosis of possible familial hypercholesterolaemia (n¼ 118) Pre- intervention (Time 2) Post- intervention (Time 4) Absolute difference 95% conﬁdence interval (%)
No. with any family history of coronary heart disease (%) 7 (5.9%) 49 (41.5%) 35.6%* 27.0, 44.2
No. with any complete family historya of coronary heart disease assessed (%) 3 (2.5%) 11 (9.3%) 6.8%* 3.5, 12.8
No. with repeat cholesterol test (%) 12 (10.2%) 101 (85.6%) 75.4%* 66.9, 82.3
No. diagnosed with secondary causeb (%) 5 (4.2%) 14 (11.9%) 7.7%* 4.1, 13.9
No. with TSH assessedc (%) 54 (45.8%) 69 (58.5%) 12.7%* 6.7, 18.7
No. with HbA1c assessedd (%) 39 (33.1%) 51 (43.2%) 10.1%* 5.9, 16.9
No. with serum creatininee (%) 103 (87.3%) 113 (95.8%) 8.5%* 4.7, 14.9
No. with bilirubin, ALP, or gamma GTf (%) 99 (83.9%) 107 (90.7%) 6.8%* 3.5, 12.8
No. with arcus senilis or xanthalasma diagnosed (%) 1 (0.8%) 8 (6.8%) 6.0%* 2.9, 11.7
*Signiﬁcant p< 0.05.
a Complete family history is deﬁned when age, condition, and degree of relation to patient is documented.
b Diabetes, hypothyroidism, chronic kidney disease, liver disease.
c Proxy for secondary investigations for hypothyroidism.
d Proxy for secondary investigations for diabetes.
e Proxy for secondary investigations for chronic kidney disease.
f Proxy for secondary investigations for liver disease.
Table 4
Change in compliance to outcomes (absolute difference) for management of 32 patients diagnosed with possible familial hypercholesterolaemia.
NICE compliance outcomes for management of familial hypercholesterolaemia (n¼ 32) Pre- intervention (Time 2) Post- intervention (Time 4) Absolute difference 95% conﬁdence interval (%)
No. prescribed any statins (%) 17 (53.1%) 23 (71.9%) 18.8%a 8.9, 35.3
No. prescribed high potency statinsa (%) 3 (9.4%) 6 (18.8%) 9.4%a 3.2, 24.2
No. given dietary or weight management advice (%) 10 (31.3%) 11 (34.4%) 3.1% 0.01, 15.7
No. given smoking cessation advice (%) 11 (34.4%) 11 (34.4%) 0% 0, 10.7
Pre- intervention (Time 2) Post- intervention (Time 4) Mean difference 95% conﬁdence interval
Mean total cholesterol in mmol/L (SD) 7.23 (1.19) 7.07 (1.22) 0.16 0.78, 0.46
Mean LDL cholesterol in mmol/L (SD) 4.58 (1.32) 4.46 (1.36) 0.12 0.81, 0.57
* Signiﬁcant p< 0.05.
a Simvastatin 80mg/day, atorvastatin 20mg/day, rosuvastatin 10mg/day.
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identiﬁcation of possible FH using systematic approaches in pri-
mary care, there have been several observational studies [18e22].
These have used nurse review of patient records [19], telephone
feedback from specialists [18], interpretative comments by spe-
cialists [23], and searches of family practice EHRs [20e22]. The
latter similar to the approach used in this study. Although previous
approaches have shown such strategies are feasible and promising,
none has assessed intervention performance against national
evidence-based guideline recommendations on the identiﬁcation
and initial management of FH.
4.1. Strengths
This studywas successful inmeasuring outcomes for patients on
all speciﬁed FH guideline recommendations, and is one of the ﬁrst
experimental studies to demonstrate changes in best practice
within six months of intervention in primary care. This included
signiﬁcant increases in repeating cholesterol testing, assessing for
family history of heart disease, diagnosing secondary causes, and
examining for clinical features of FH, while also increasing statin
prescribing for those diagnosed with possible FH. Although there
was no signiﬁcant decrease in mean total cholesterol or LDL-
cholesterol within the brief follow up period, this simple inter-
vention nevertheless identiﬁed individuals with possible FH who
were previously unrecognised and who are beneﬁting from lipid
lowering therapies.
The intervention was successfully implemented in general
practices from populations with higher levels of socio-economic
deprivation, with variation of uptake from 8 to 15% from the four
inner city practices, 14% from the suburban practice, and 27% from
the urban practice [14]. While lower rates of FH diagnosis, higher
levels of premature coronary heart disease [24], and poorer man-
agement of patients with increased cardiovascular risk [25] are
more common in this context, improvements in compliance to
guideline recommendations were still demonstrated.
Finally, wewere able to combine outcome data from both coded
EHR searches and free text in manual review of the clinical records
to enhance the completeness of the outcome measures. This pro-
cess is consistent with previous studies on FH identiﬁcation using
both EHRs and manual review [20,22].
4.2. Limitations
Within the constraints of the short study period, a relatively
modest number of eligible patients were engaged and agreed to
assessment, but this was sufﬁcient for the speciﬁed study sample
size. The lower uptake of eligible patients with elevated cholesterol
was also due to purposeful recruitment in areas of low deprivation
(4/6 practices). It is recognised that patients from these deprived
UK areas may face greater challenges in engaging with preventive
and primary health care in the context of multiple morbidities and
competing health and other life priorities [26].
The six-month follow-up period did not allow for full review
and access to secondary care outcomes for the 32 patients who
were diagnosed with possible FH. This includes conﬁrming the
diagnosis by genetic testing for the monogenic mutation.
The primary limitation of this exploratory study is its non-
randomised and uncontrolled design; therefore the observed
changes in compliance to NICE guideline recommendations must
be interpreted with caution, as they may not be directly attribut-
able to the intervention. Other potential external inﬂuences could
include the recently introduced UK Department of Health vascular
check (CVD risk assessment programmes) [27] or release of revised
NICE lipid modiﬁcation guidelines that brieﬂy highlight theimportance of identifying FH [28,29], though there is no evidence of
their major impact on routine primary care practice given contin-
uous under-diagnosis of FH in primary care [2].
Finally, in line with NICE guideline recommendations, only
those patients who have ever had a cholesterol above the threshold
(>7.5mmol) were assessed. However, from our search of EHRs, we
observed some patients below this threshold were prescribed
statins prior to their cholesterol result entry. These individuals
could have had possible FH. Systematic approaches to account for
treatment effects as well as other relevant clinical criteria are
currently being developed. [22,30e33].
4.3. Conclusion
This study shows the promise of a simple intervention to
improve identiﬁcation and management of possible familial
hypercholesterolaemia in line with clinical guideline recommen-
dations. If this simple intervention was rolled out across primary
care, this could lead to a substantial improvement in recognition of
possible FH leading to improved health outcomes for these in-
dividuals through targeted specialist follow-up and management.
Further testing of this intervention is merited, using a cluster-
randomised controlled design, with a longer study period to
improve patient engagement and assessment of longer-term
outcomes.
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